Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 18/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 17/20 | 0.51 |
| ▸ | FNTB | P49356 | 15/20 | 0.51 |
| ▸ | DNAJA1 | P31689 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7252683 | 0.99 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7248216 | 0.82 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7252273 | 0.82 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| Hydrochloric Acid SCHEMBL7247014 | 0.81 | FNTA (0.50) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| Hydrochloric Acid SCHEMBL7253913 | 0.81 | FNTA (0.50) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| Hydrochloric Acid SCHEMBL7248127 | 0.81 | FNTA (0.50) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7184432 | 0.77 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7181655 | 0.77 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7184844 | 0.77 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7185080 | 0.77 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534506-B2 | For therapy of cancer, neurofibromin benign proliferative disorder; blindness related to retinal vascularization; infections from hepatitis delta and related viruses; prophylaxis of restenosis; polycystic kidney disease | MERCK & CO., INC. | 2003-03-18 | — | — | US | claimed |
| US-20020123497-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-09-05 | — | — | US | claimed |
| WO-2001077116-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-10-18 | — | — | WO | claimed |
| US-6534506-B2 | For therapy of cancer, neurofibromin benign proliferative disorder; blindness related to retinal vascularization; infections from hepatitis delta and related viruses; prophylaxis of restenosis; polycystic kidney disease | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020123497-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-09-05 | — | — | US | disclosed |
| WO-2001077116-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123497-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | FNTA 1/4885PGGT1B 122/4885FNTB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.